Title Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients : Asia psychotropic prescripton study
暂无分享,去创建一个
R. Baldessarini | Chuan-Yue Wang | T. Si | Y. Chan | K. Sim | E. Kua | N. Sartorius | G. Ungvari | Y. Xiang | E. Lee | M. Chong | J. Trivedi | N. Shinfuku | Chay-Hoon Tan | E. Chung | K. Chee | S. Fujii | Shu-Yu Yang | P. Tor | P. Udomratn | Yan-ling He | K. Yong | Chuanyue Wang
[1] S. Leucht,et al. Valproate for schizophrenia. , 2016, The Cochrane database of systematic reviews.
[2] D. Kelly,et al. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements , 2012 .
[3] G. Fitzmaurice,et al. Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients , 2011, International clinical psychopharmacology.
[4] R. Baldessarini,et al. International consensus study of antipsychotic dosing. , 2010, The American journal of psychiatry.
[5] R. Baldessarini,et al. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004 , 2010, Human psychopharmacology.
[6] Hannah F Jones,et al. Antiepileptics for aggression and associated impulsivity. , 2010, The Cochrane database of systematic reviews.
[7] L. Citrome. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? , 2009, Expert review of neurotherapeutics.
[8] O. Andreassen,et al. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders , 2009, Acta psychiatrica Scandinavica.
[9] M. Valenstein,et al. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. , 2007, Psychiatric services.
[10] J. Mallinger,et al. Racial differences in the use of adjunctive psychotropic medications for patients with schizophrenia. , 2007, The journal of mental health policy and economics.
[11] P. Gorwood. Meeting everyday challenges: Antipsychotic therapy in the real world , 2006, European Neuropsychopharmacology.
[12] H. Meltzer,et al. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release , 2005, Brain Research.
[13] S. Leucht,et al. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials , 2004, Schizophrenia Research.
[14] S. Heckers,et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. , 2004, British journal of clinical pharmacology.
[15] T. Si,et al. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. , 2004, Pharmacopsychiatry.
[16] S. Stahl. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. , 2004, The Journal of clinical psychiatry.
[17] F. Trémeau,et al. A Study of the Safety, Efficacy, and Tolerability of Switching From the Standard Delayed Release Preparation of Divalproex Sodium to the Extended Release Formulation in Patients With Schizophrenia , 2004, Journal of clinical psychopharmacology.
[18] L. Kochan,et al. GABA and Schizophrenia: A Review of Basic Science and Clinical Studies , 2003, Journal of clinical psychopharmacology.
[19] R. Buchanan,et al. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. , 2002, The American journal of psychiatry.
[20] G. Simpson,et al. Psychopharmacology: rational and irrational polypharmacy. , 2001, Psychiatric services.
[21] John E. Cooper,et al. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR) , 2001, British Journal of Psychiatry.
[22] G. Winterer,et al. Valproate and the symptomatic treatment of schizophrenia spectrum patients. , 2000, Pharmacopsychiatry.
[23] J. Levine,et al. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. , 2000, Psychiatric services.
[24] J. Guelfi,et al. Guidelines for depot antipsychotic treatment in schizophrenia , 1998, European Neuropsychopharmacology.
[25] C. Galletly,et al. Antipsychotic Drug Doses and Adjunctive Drugs in the Outpatient Treatment of Schizophrenia , 1997, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[26] A. Llerena,et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. , 1995, British journal of clinical pharmacology.
[27] T. Terao,et al. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double‐blind, placebo‐controlled, cross‐over study , 1995, Acta psychiatrica Scandinavica.
[28] W. Wilson. Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial , 1993, Psychopharmacology.
[29] E. Larkin,et al. Lithium carbonate in chronic schizophrenia — a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients , 1991, Acta psychiatrica Scandinavica.
[30] H. Emrich,et al. Carbamazepine as an adjunct of antipsychotic therapy , 1987, Psychiatry Research.
[31] R. Conley,et al. Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia , 2006, Psychiatric Quarterly.
[32] J. Haro,et al. The SOHO (Schizophrenia Outpatient Health Outcome) Study , 2006, CNS drugs.
[33] R. Petty,et al. Valproate for hostility in schizophrenia patients. , 2004, The Journal of clinical psychiatry.
[34] J. Guelfi,et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. , 1998, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.
[35] J. van os,et al. Do we need a European consensus on the use of antipsychotic medication? , 1996, European Psychiatry.
[36] G. Braemer. International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.